American Journal of Clinical Dermatology

, Volume 2, Issue 4, pp 253–262 | Cite as

Drug-Induced Skin Pigmentation

Epidemiology, Diagnosis and Treatment
Review Article

Abstract

Drug-induced pigmentation represents 10 to 20% of all cases of acquired hyperpigmentation and this hypothesis must be systematically raised in unexplained pigmented lesions especially in elderly people. The pathogenesis of drug-induced pigmentation is variable according to the causative medication and can involve an accumulation of melanin, sometimes following a nonspecific cutaneous inflammation and often worsened by sun exposure, an accumulation of the triggering drug itself, a synthesis of special pigments under the direct influence of the drug or deposits of iron following damage to the dermal vessels.

The influence of sun exposure is usually obvious in most cases, either by sun-induced melanin synthesis stimulation with formation of complexes between melanin and the causative drug or by transformation of the drug in visible particles usually taken up by dermal macrophages under the influence of sunlight.

The main drugs implicated in causing skin pigmentation are nonsteroidal anti-inflammatory drugs, antimalarials, amiodarone, cytotoxic drugs, tetracyclines, heavy metals and psychotropic drugs. Clinical features are very variable according to the triggering molecule, with a large range of patterns and shades which are sometimes more or less reminiscent of the culprit drug. Histological findings are very variable as well but the colored particles are often concentrated within dermal macrophages which are sometimes localized in a distinctive fashion with respect to dermal structures such as vessels or adnexes. Treatment is often limited to sun-avoidance or interruption of treatment with the offending drug but laser therapy recently gave rise to hope of a cure in some cases. These measures are often followed by a fading of the lesions but the pigmentation may last for a long time or may even become permanent in a small percentage of patients.

References

  1. 1.
    Levantine A., Almeyda J. Drug induced changes in pigmentation. Br J Dermatol 1973; 89: 105–112PubMedCrossRefGoogle Scholar
  2. 2.
    Granstein R.D., Sober A.J. Drug- and heavy-metal-induced hyperpigmentation. J Am Acad Dermatol 1981; 5: 1–18PubMedCrossRefGoogle Scholar
  3. 3.
    Fitzpatrick J.E. New histopathologic findings in drug eruptions. Dermatol Clin 1992; 10: 19–36PubMedGoogle Scholar
  4. 4.
    Zurcher K., Krebs A. Cutaneous drug reactions. Basel, Karger, 1992Google Scholar
  5. 5.
    Dubois E.L. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 1978; 8: 33–51PubMedCrossRefGoogle Scholar
  6. 6.
    Koranda F.C. Antimalarials. J Am Acad Dermatol 1981; 4: 650–655PubMedCrossRefGoogle Scholar
  7. 7.
    Bailin P.L., Matkaluk R.M. Cutaneous reactions to rheumatological drugs. Clin Rheum Dis 1982; 8: 493–516PubMedGoogle Scholar
  8. 8.
    Ribrioux A. Synthetic antimalarials and skin. Ann Dermatol Venereol 1990; 117: 975–990PubMedGoogle Scholar
  9. 9.
    Delage C., Lagace R., Huard J. Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study. Can Med Assoc J 1975; 112: 1205–1208PubMedGoogle Scholar
  10. 10.
    Susser W.S., Whitaker-Worth D.L., Grant-Kels J.M. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40; 367–398PubMedCrossRefGoogle Scholar
  11. 11.
    Bronner A., Hood A. Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol 1983; 9: 645–663PubMedCrossRefGoogle Scholar
  12. 12.
    Harrison B., Wood C. Cyclophosphamide and pigmentation. BMJ 1972; 1: 352CrossRefGoogle Scholar
  13. 13.
    Pratt C.B., Shanks E.C. Hyperpigmentation of nails from doxorubicin. JAMA 1974; 228: 460PubMedCrossRefGoogle Scholar
  14. 14.
    Werner Y., Thornberg B. Cutaneous side effects of bleomycin therapy. Acta Derm Venereol 1976; 56: 155–158PubMedGoogle Scholar
  15. 15.
    Hrushesky W. Unusual pigmentary changes associated with 5-fluorouracil therapy. Cutis 1980; 26: 181–182PubMedGoogle Scholar
  16. 16.
    Guillet G., Guillet M., DeMeaux H., et al. Cutaneous pigmented stripes and bleomycin treatment. Arch Dermatol 1986; 122: 381–382PubMedCrossRefGoogle Scholar
  17. 17.
    Kumar L., Kochipillai V. Mitoxantrone induced hyperpigmentation. N Z Med J 1990; 103: 55PubMedGoogle Scholar
  18. 18.
    Llistosella E., Codina A., Alvarez R., et al. Tegafur-induced acral hyperpigmentation. Cutis 1991; 48: 205–207PubMedGoogle Scholar
  19. 19.
    Perlin E., Ahlgren J. Pigmentary effects from the protracted infusion of 5-fluorouracil. Int J Dermatol 1991; 30: 43–44PubMedCrossRefGoogle Scholar
  20. 20.
    Hendrix J., Greer K. Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol 1992; 31: 458–466PubMedCrossRefGoogle Scholar
  21. 21.
    Konohama A. Blue-gray pigmentation in a patient receiving doxorubicin. J Dermatol 1992; 19: 250–252Google Scholar
  22. 22.
    Gropper C., Don P., Sadjadi M. Nail and skin hyperpigmentation associated with hydroxyurea therapy for polycythemia vera. Int J Dermatol 1993; 32: 731–733PubMedCrossRefGoogle Scholar
  23. 23.
    Yule S., Pearson A., Craft A. Ifosfamide-induced hyperpigmentation. Cancer 1994; 73: 240–241PubMedCrossRefGoogle Scholar
  24. 24.
    Allen B., Parker D., Wright A. Reticulate pigmentation due to 5-fluorouracil. Int J Dermatol 1995; 34: 219–220PubMedCrossRefGoogle Scholar
  25. 25.
    Baselga E., Drolet B., Casper J., et al. Chemotherapy-associated supravenous hyperpigmentation. Dermatology 1996; 192: 384–385PubMedCrossRefGoogle Scholar
  26. 26.
    Kwong Y. Hydroxyurea-induced nail pigmentation. J Am Acad Dermatol 1996; 35: 275–276PubMedCrossRefGoogle Scholar
  27. 27.
    Borecky D., Stephenson J., Keeling J., et al. Idarubicin-induced pigmentary changes of the nail. Cutis 1997; 59: 203–204PubMedGoogle Scholar
  28. 28.
    McGrae J.D., Zelickson A.S. Skin pigmentation secondary to minocycline therapy. Arch Dermatol 1980; 116: 1262–1265PubMedCrossRefGoogle Scholar
  29. 29.
    Simons J.J., Morales A. Minocycline and generalized cutaneous pigmentation. J Am Acad Dermatol 1980; 3: 244–247PubMedCrossRefGoogle Scholar
  30. 30.
    Patel K., Cheshire D., Vance A. Oral and systemic effects of prolonged minocycline therapy. Br Dent J 1998; 26; 185: 560–562CrossRefGoogle Scholar
  31. 31.
    Eisen D., Hakim M.D. Minocycline-induced pigmentation. Incidence, prevention and management. Drug Saf 1998; 18: 431–440PubMedCrossRefGoogle Scholar
  32. 32.
    Fraunfelder F.T., Randall J.A. Minocycline-induced scleral pigmentation. Ophthalmology 1997; 104: 936–938PubMedGoogle Scholar
  33. 33.
    Pepine M., Flowers F.P., Ramos-Caro F.A. Extensive cutaneous hyperpigmentation caused by minocycline. J Am Acad Dermatol 1993; 28: 292–295PubMedCrossRefGoogle Scholar
  34. 34.
    Noble J.G., Christmas T.J., Chapple C., et al. The black thyroid: an unusual finding during neck exploration. Postgrad Med J 1989; 65: 34–35PubMedCrossRefGoogle Scholar
  35. 35.
    Beurey J., Weber M., Jeandel C., et al. Argyria. Therapie 1986; 41: 505–510PubMedGoogle Scholar
  36. 36.
    Bleehen S.S., Gould D.J., Harrington C.I., et al. Occupational argyria: light and electron microscopic studies and x-ray microanalysis. Br J Dermatol 1981; 104: 19–26PubMedCrossRefGoogle Scholar
  37. 37.
    White M.I. Localized argyria caused by silver earrings. Br J Dermatol 1997; 136: 980PubMedCrossRefGoogle Scholar
  38. 38.
    Suzuki H., Baba S., Uchigasaki S., et al. Localized argyria with chrysiasis caused by implanted acupuncture needles: distribution and chemical forms of silver and gold in cutaneous tissue by electron microscopy and x-ray microanalysis. J Am Acad Dermatol 1993; 29: 833–837PubMedCrossRefGoogle Scholar
  39. 39.
    Legat F.J., Goessler W., Schlagenhaufen C., et al. Argyria after short-contact acupuncture. Lancet 1998; 352: 241PubMedCrossRefGoogle Scholar
  40. 40.
    Massi D., Santucci M. Human generalized argyria: a submicroscopic and x-ray spectroscopic study. Ultrastruct Pathol 1998; 22: 47–53PubMedCrossRefGoogle Scholar
  41. 41.
    Smith R.W., Leppard B., Barnett N.L., et al. Chrysiasis revisited: a clinical and pathological study. Br J Dermatol 1995; 131: 671–678Google Scholar
  42. 42.
    Cremer B., Czarnetzki B.M. Skin discolorations under gold jewelry. Dtsch Med Wochenschr 1992; 117: 558PubMedGoogle Scholar
  43. 43.
    Trotter M.J., Tron V.A., Hollingdale J., et al. Localized chrysiasis induced by laser therapy. Arch Dermatol 1995; 131: 1411–1414PubMedCrossRefGoogle Scholar
  44. 44.
    al-Talib R.K., Wright D.H., Theaker J.M. Orange-red birefringence of gold particles in paraffin wax embedded sections: an aid to the diagnosis of chrysiasis. Histopathology 1994; 24: 176–178PubMedCrossRefGoogle Scholar
  45. 45.
    Culora G.A., Barnett N., Theaker J.M. Artefacts in electron microscopy: ultrastructural features of chrysiasis. J Pathol 1995; 176: 421–425PubMedCrossRefGoogle Scholar
  46. 46.
    Wolf M.E., Richer S., Berk M.A., et al. Cutaneous and ocular changes associated with the use of chlorpromazine. Int J Clin Pharmacol Ther Toxicol 1993; 31: 365–367PubMedGoogle Scholar
  47. 47.
    Mars U., Larsson B.S. Pheomelanin as a binding site for drugs and chemicals. Pigment Cell Res 1999; 12: 266–274PubMedCrossRefGoogle Scholar
  48. 48.
    Carter R.J., Shuster S. Melanocyte-stimulating hormone-mimetic action of the phenothiazines. J Pharm Pharmacol 1978; 30: 233–235PubMedCrossRefGoogle Scholar
  49. 49.
    Buckley C., Thomas V., Lewin J., et al. Stelazine-induced pigmentation. Clin Exp Dermatol 1994; 19: 149–151PubMedCrossRefGoogle Scholar
  50. 50.
    Bloom D., Krishnan B., Thavundayil J.X., et al. Resolution of chlorpromazine-induced cutaneous pigmentation following substitution with levomepromazine or other neuroleptics. Acta Psychiatr Scand 1993; 87: 223–224PubMedCrossRefGoogle Scholar
  51. 51.
    Lal S., Bloom D., Silver B., et al. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci 1993; 18: 173–177PubMedGoogle Scholar
  52. 52.
    O’Croinin F., Zibin T. Re: Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci 1994; 19: 226PubMedGoogle Scholar
  53. 53.
    Hare P.J. ‘Visage rouge’ from imipramine. Br J Dermatol 1970; 83: 420PubMedCrossRefGoogle Scholar
  54. 54.
    Sicari M.C., Lebwohl M., Baral J., et al. Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. J Am Acad Dermatol 1999; 40: 290–293PubMedCrossRefGoogle Scholar
  55. 55.
    Narurkar V., Smoller B.R., Hu C.H., et al. Desipramine-induced blue-gray photosensitive pigmentation. Arch Dermatol 1993; 129: 474–476PubMedCrossRefGoogle Scholar
  56. 56.
    Atkin D.H., Fitzpatrick R.E. Laser treatment of imipramine-induced hyperpigmentation. J Am Acad Dermatol 2000; 43: 77–80PubMedCrossRefGoogle Scholar
  57. 57.
    Karat A.B.A., Jeevaratnam A., Karat S., et al. Controlled clinical trial of clofazimine in untreated lepromatous leprosy. BMJ 1971; iv: 514–516CrossRefGoogle Scholar
  58. 58.
    Holdiness M.R. A review of the Redman syndrome and rifampicin overdosage. Med Toxicol Adverse Drug Exp 1989; 4: 444–451PubMedGoogle Scholar
  59. 59.
    Greenberg R.G., Berger T.G. Nail and mucocutaneous hyperpigmentation with azidothymidine therapy. J Am Acad Dermatol 1990; 22: 327–330PubMedCrossRefGoogle Scholar
  60. 60.
    Gallais V., Lacour J.P., Perrin C., et al. Acral hyperpigmented macules and longitudinal melanonychia in AIDS patients. Br J Dermatol 1992; 126: 387–391PubMedCrossRefGoogle Scholar
  61. 61.
    Gallais V., Lacour J.P., Ortonne J.P. Cutaneous pigmentation disorders in human immunodeficiency virus infection. Ann Dermatol Venereol 1992; 119: 471–478PubMedGoogle Scholar
  62. 62.
    Lascari A.D. Carotemia. Clin Pediatr (Bologna) 1981; 20: 25–29CrossRefGoogle Scholar
  63. 63.
    Hammer C.J., Melasma induced by oral contraceptive drugs. N W Med Seattle 1968; 67: 251–254Google Scholar
  64. 64.
    Baker H. Adverse cutaneous reactions to oral contraceptives. Br J Dermatol 1969; 81: 946–949PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Department of Dermatology-PhlebologyUniversity Hospital of Montpellier, Hôpital Saint-EloiMontpellier Cedex 5France

Personalised recommendations